G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring orthopedic ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...